Home › Multiple Myeloma › Indiana
Pag-aaral pangklinika para sa Multiple Myeloma sa Indiana
19 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa Indiana.
Mga Lungsod sa Indiana
Opisyal na teksto ng pag-aaral (English)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 101, Fort Wayne
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07582432A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Franciscan Health, Indianapolis
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Indiana University, Indianapolis
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05201781A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Genesis Medical Research, Dyer
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07477587A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Fort Wayne Medical Oncology And Hematology /ID# 278141, Fort Wayne
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Indiana University Health Arnett, Inc., Lafayette
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07648264Collection of Tissue Samples for Cancer Research
- Indiana University - Purdue, Indianapolis
Nagre-recruitObservasyonal na pag-aaral
2 Months · Lahat ng kasarian · Na-update Set 16, 2026 · NCT00900198MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- IU Health North Hospital, Carmel
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04566328A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Indiana University, Indianapolis
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Indiana University Health, Indianapolis
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07284758A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fort Wayne Medical Oncology And Hematology /ID# 268179, Fort Wayne
- Franciscan St. Francis Health /ID# 280928, Indianapolis
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Indiana University Health Simon Cancer Center, Indianapolis
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 8, 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Community Health Network, Indianapolis
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- IU Health North Hospital, Carmel
- Northwest Cancer Center - Main Campus, Crown Point
- Northwest Oncology LLC, Dyer
- at 8 pa
Nagre-recruitPhase 3
Lahat ng edad · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT05561387cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT05366881The Indiana Myeloma Registry
- Indiana University Simon Cancer Center, Indianapolis
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2025 · NCT03616483Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.